Secretome Therapeutics Receives $250,000 from PPMD to Advance Cardiac Cell Therapy
Secretome Therapeutics was awarded $250,000 by Parent Project Muscular Dystrophy (PPMD) through its Venture Pathways program to support development of STM‑01, a neonatal cardiac progenitor cell therapy targeting cardiomyopathy in Duchenne muscular dystrophy. The funding will accelerate preclinical work aimed at reducing inflammation, fibrosis, and improving heart function, addressing the leading cause of death in Duchenne patients. This collaboration highlights Secretome’s innovative approach and PPMD’s ongoing commitment to advancing cardiac therapies for the Duchenne community. 
Secretome Therapeutics Receives $250,000 from PPMD to Advance Cardiac Cell Therapy